DK1007040T3 - Anvendelsen af phanquinon til behandlingen af Alzheimers sygdom - Google Patents

Anvendelsen af phanquinon til behandlingen af Alzheimers sygdom

Info

Publication number
DK1007040T3
DK1007040T3 DK98930970T DK98930970T DK1007040T3 DK 1007040 T3 DK1007040 T3 DK 1007040T3 DK 98930970 T DK98930970 T DK 98930970T DK 98930970 T DK98930970 T DK 98930970T DK 1007040 T3 DK1007040 T3 DK 1007040T3
Authority
DK
Denmark
Prior art keywords
alzheimer
disease
treatment
phanquinone
prevention
Prior art date
Application number
DK98930970T
Other languages
Danish (da)
English (en)
Inventor
Michel Xilinas
Panayotis Nikolas Gerolymatos
Original Assignee
Gerolymatos P N Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gerolymatos P N Sa filed Critical Gerolymatos P N Sa
Application granted granted Critical
Publication of DK1007040T3 publication Critical patent/DK1007040T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
DK98930970T 1997-08-21 1998-07-17 Anvendelsen af phanquinon til behandlingen af Alzheimers sygdom DK1007040T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GR97100330 1997-08-21
GR97100507 1997-12-31
PCT/IB1998/001095 WO1999009981A1 (en) 1997-08-21 1998-07-17 Use of phanquinone for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
DK1007040T3 true DK1007040T3 (da) 2002-08-26

Family

ID=26316681

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98930970T DK1007040T3 (da) 1997-08-21 1998-07-17 Anvendelsen af phanquinon til behandlingen af Alzheimers sygdom

Country Status (25)

Country Link
US (2) US6670369B1 (is)
EP (1) EP1007040B1 (is)
JP (1) JP2001513558A (is)
CN (1) CN1145482C (is)
AT (1) ATE217191T1 (is)
AU (1) AU741782B2 (is)
BG (1) BG64300B1 (is)
BR (1) BR9814945A (is)
CA (1) CA2301706C (is)
CZ (1) CZ299739B6 (is)
DE (1) DE69805305T2 (is)
DK (1) DK1007040T3 (is)
EA (1) EA002526B1 (is)
ES (1) ES2177024T3 (is)
HK (1) HK1029937A1 (is)
HU (1) HUP0004331A3 (is)
IL (1) IL134263A (is)
IS (1) IS1910B (is)
NO (1) NO317770B1 (is)
NZ (1) NZ502565A (is)
PL (1) PL191208B1 (is)
PT (1) PT1007040E (is)
SK (1) SK284708B6 (is)
TR (1) TR200000455T2 (is)
WO (1) WO1999009981A1 (is)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045531B1 (en) 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
US5994323A (en) * 1997-12-31 1999-11-30 P.N. Gerolymatos S.A. Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof
US6323218B1 (en) 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US6638711B1 (en) 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
ATE285235T1 (de) * 1999-01-07 2005-01-15 Gerolymatos P N Sa Verwendung von phanquinon zur behandlung und vorbeugung von gedächtnisschwund
WO2001082912A2 (en) * 2000-04-28 2001-11-08 Gerolymatos P N Sa TREATMENT OF PATHOLOGICAL CONDITIONS INFLUENCED BY THE ACTION OF MATRIX METALLOPROTEINASES (MMPs) USING PHANQUINONE
AU2001250571A1 (en) * 2000-04-28 2001-11-12 P.N. Gerolymatos S.A. Treatment of pathological conditions influenced by the action of matrix metalloproteinases (mmps) using clioquinol
EP1311299A4 (en) 2000-08-18 2008-01-02 Gen Hospital Corp METHOD OF IDENTIFICATION AND USE OF SUBSTANCES WHICH CATEGORIZE OR PROMOTE CATARACTA
FR2818551B1 (fr) * 2000-12-22 2007-06-01 Claude Marc Pierre Hannoun Utilisation de chelateurs pour le traitement des maladies a prions
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
WO2004080208A1 (ja) * 2003-03-11 2004-09-23 Kaneka Corporation コエンザイムｑ１０を含有した水中油型乳化組成物、及びその製法
US20080207673A1 (en) * 2005-05-04 2008-08-28 Michel Xilinas Method for Treating Cancer, Coronary, Inflammatory and Macular Disease, Combining the Modulation of Zinc-and/or Copper Dependent Proteins
JP6692755B2 (ja) * 2014-04-29 2020-05-13 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ アルツハイマー病（ａｄ）の処置および予防

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617417A1 (de) * 1966-12-08 1971-03-25 Ciba Geigy Pharmazeutisches Praeparat
DE1804736A1 (de) * 1967-11-02 1969-06-26 Ciba Geigy Pharmazeutisches Praeparat
IL40311A (en) 1972-09-06 1973-04-30 Pharmaplantex Ltd Pharmaceutical preparation for the treatment of gastro-intestinal troubles containing phanquone and furazolidone
GB1472257A (en) 1973-09-10 1977-05-04 Christiaens Sa A Derivative of 4-hydroxy-5-azacoumarin
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US4981844A (en) * 1988-10-04 1991-01-01 University Of Cincinnati Method to improve immune response and resistance to infection following surgery by diet composition
US5091391A (en) * 1990-08-16 1992-02-25 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of resisting neurodegenerative disorders
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
AP387A (en) * 1991-09-13 1995-07-31 Siegbert Heinrich Bissbort Therapeutical uses of L-methionine and compositions thereof.
DE69227380T3 (de) 1991-11-12 2007-01-11 Prana Biotechnology Ltd., South Melbourne Verfahren zur bestimmung und behandlung von alzheimer-krankheit
GB9126874D0 (en) * 1991-12-18 1992-02-19 Wellcome Found Medicaments
AU6580494A (en) * 1994-05-11 1995-12-05 P.N. Gerolymatos S.A. Use of clioquinol for treating helicobacter, including (h. pylori), infections and related diseases
AU1153097A (en) * 1996-06-07 1998-01-05 Eisai Co. Ltd. Stable polymorphs of donepezil (1-benzyl-4-{(5,6-dimethoxy-1-indanon)-2-yl}methylpiperidine ) hydrochloride and process for production
HUP9903906A3 (en) * 1996-08-13 2001-01-29 Gerolymatos P N Sa Use of chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
EP1007048A4 (en) 1997-03-11 2004-09-22 Gen Hospital Corp IDENTIFICATION OF AGENTS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE
US5980882A (en) * 1997-04-16 1999-11-09 Medeva Pharmaceuticals Manufacturing Drug-resin complexes stabilized by chelating agents
US5980914A (en) 1997-08-22 1999-11-09 P.N. Gerolymatos S.A. Clioquinol for the treatment of Parkinson's disease
US5994323A (en) 1997-12-31 1999-11-30 P.N. Gerolymatos S.A. Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof
ATE285235T1 (de) * 1999-01-07 2005-01-15 Gerolymatos P N Sa Verwendung von phanquinon zur behandlung und vorbeugung von gedächtnisschwund
WO2001082912A2 (en) 2000-04-28 2001-11-08 Gerolymatos P N Sa TREATMENT OF PATHOLOGICAL CONDITIONS INFLUENCED BY THE ACTION OF MATRIX METALLOPROTEINASES (MMPs) USING PHANQUINONE
AU2001250571A1 (en) 2000-04-28 2001-11-12 P.N. Gerolymatos S.A. Treatment of pathological conditions influenced by the action of matrix metalloproteinases (mmps) using clioquinol

Also Published As

Publication number Publication date
BG104179A (en) 2000-10-31
DE69805305T2 (de) 2002-12-05
BG64300B1 (bg) 2004-09-30
TR200000455T2 (tr) 2000-09-21
CZ299739B6 (cs) 2008-11-05
SK2062000A3 (en) 2000-08-14
HUP0004331A3 (en) 2001-09-28
PL338673A1 (en) 2000-11-20
CN1145482C (zh) 2004-04-14
CZ2000611A3 (cs) 2000-08-16
SK284708B6 (sk) 2005-09-08
CA2301706A1 (en) 1999-03-04
HUP0004331A2 (hu) 2001-05-28
IL134263A0 (en) 2001-04-30
IL134263A (en) 2006-04-10
PL191208B1 (pl) 2006-03-31
AU741782B2 (en) 2001-12-06
EP1007040A1 (en) 2000-06-14
DE69805305D1 (de) 2002-06-13
AU8124198A (en) 1999-03-16
CA2301706C (en) 2005-10-04
IS1910B (is) 2003-12-31
BR9814945A (pt) 2000-09-05
PT1007040E (pt) 2002-10-31
ES2177024T3 (es) 2002-12-01
EP1007040B1 (en) 2002-05-08
NO20000771D0 (no) 2000-02-16
EA002526B1 (ru) 2002-06-27
CN1267218A (zh) 2000-09-20
US6670369B1 (en) 2003-12-30
IS5366A (is) 2000-01-28
NO317770B1 (no) 2004-12-13
NZ502565A (en) 2002-03-01
WO1999009981A1 (en) 1999-03-04
ATE217191T1 (de) 2002-05-15
EA200000242A1 (ru) 2000-08-28
US20050003018A1 (en) 2005-01-06
HK1029937A1 (en) 2001-04-20
US7629354B2 (en) 2009-12-08
NO20000771L (no) 2000-04-25
JP2001513558A (ja) 2001-09-04

Similar Documents

Publication Publication Date Title
IS4972A (is) Notkun klóbindiefnisins klíókínól við að framleiða lyfjablöndu til að meðhöndla Alzheimers-sjúkdóm
TR199902071T2 (xx) Heterosiklik bile�ikler ve bunlar�n �-amilioid peptidinin inhibisyonunda kullan�m�
HUP9700603A1 (hu) Gyógyászati készítmény véralvadási zavarok kezelésére
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
NO20022531D0 (no) Vaksine for forebyggelse og behandling av Alzheimer og amyloidrelaterte sykdommer
DK1007040T3 (da) Anvendelsen af phanquinon til behandlingen af Alzheimers sygdom
NO972391D0 (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
NO20001869L (no) FremgangsmÕte for behandling av Alzheimers sykdom
EA199700151A1 (ru) Композиция для чрескожного введения
BR9711225A (pt) Composi-{es de propentofilina transd-rmica para o tratamento do mal de alzheimer
DE69420229D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
TR200000291T2 (tr) Taşikinin reseptör antagonistleri olarak 2-asilaminopropanaminler.
MX9707642A (es) Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos.
PT1131297E (pt) Certas caprolactamas substituidas composicoes farmaceuticas contendo-as e sua utilizacao no tratamento de tumores
PT888114E (pt) Utilizacao de (+)-alfa-(2,3-dimetoxifenil)-1-¬2-(4-fluorofenil)etil|-4-piperidinometanol no tratamento de doencas depressivas e doencas bipolares
PT1152762E (pt) Utilizacao de desoxipeganina no tratamento da demencia de alzheimer
DK0836853T3 (da) Anvendelse af bradykinin-antagonister til fremstilling af lægemidler til behandling og forebyggelse af Alzheimers sygdom
DK0703781T3 (da) Anvendelse af Efaroxan og derivater deraf til fremstilling af et lægemiddel til behandling af Parkinsons sygdom
NO953072L (no) Anvendelse av inhibitorer av ornitinaminotransferase for fremstilling av et medikament for behandling av Alzheimers sykdom
RS49595B (sr) Primena 2-fenil-1,2- benzizoselenazol-3(2h)-ona za izradu farmaceutskog preparata za lečenje alchajmerove bolesti
DK1152762T3 (da) Anvendelse af desoxypeganin til behandling af Alzheimers demens